Clinical Scorecard: Kidney Transplant Candidates with High Sensitization: A Comprehensive Approach to Acceptable Mismatches, Desensitization Techniques, Imlifidase, and Innovative Immune-Cell Targeting Methods
At a Glance
Category
Detail
Condition
Highly sensitized kidney transplant candidates
Key Mechanisms
Anti-human leukocyte antigen (HLA) sensitization restricts access to compatible organs, increasing the risk of antibody-mediated rejection (AMR).
Target Population
Patients with high sensitization levels requiring kidney transplantation.
Care Setting
Transplantation centers and allocation programs.
Key Highlights
Management requires a combination of strategies beyond antibody characteristics.
Compatible transplantation is preferred and can be achieved through various allocation strategies.
Desensitization is an access-enabling intervention for selected candidates.
Imlifidase can facilitate rapid access to transplantation but is associated with frequent AMR.
Emerging immune-cell targeting strategies are investigational.
Guideline-Based Recommendations
Diagnosis
Assess sensitization using metrics like panel-reactive antibody (PRA), calculated PRA (cPRA), and virtual PRA (vPRA).
Management
Utilize compatibility-first access framework and prioritize compatible transplantation.
Consider desensitization and imlifidase for candidates without realistic compatible options.
Monitoring & Follow-up
Implement strict governance and surveillance post-transplantation, especially for imlifidase recipients.
Risks
Increased risk of antibody-mediated rejection (AMR) with incompatible transplants.
Patient & Prescribing Data
Highly sensitized kidney transplant candidates with limited access to compatible organs.
Compatible pathways should be optimized before considering intervention-based strategies.
Clinical Best Practices
Integrate immunologic precision and structured monitoring into the management strategy.
Utilize allocation priority based on expert-defined acceptable antigens.
